司库奇尤单抗治疗强直性脊柱炎5年疗效与安全性:MEASURE 2研究终期结果
MEASURE 2是一项3期双盲随机安慰剂对照研究,报告司库奇尤单抗150 mg皮下注射治疗强直性脊柱炎5年结果。150 mg组5年时ASAS20应答为67%(36/54),ASAS40为50%(27/54),BASDAI50为53%(44/83),ASDAS-CRP无活动性疾病为21%(17/81),安全性特征与既往报告一致。
要点
- 司库奇尤单抗150 mg治疗5年维持ASAS20/40及BASDAI50应答。
- 5年ASDAS-CRP无活动性疾病比例21%,ASAS部分缓解25%。
- 安全性特征与既往报告一致,未观察到新的安全信号。
核心结论
- 司库奇尤单抗150 mg治疗强直性脊柱炎5年维持症状、体征和躯体功能改善,安全性特征与既往报告一致。
研究设计与样本
- MEASURE 2为3期双盲随机安慰剂对照研究,在13个国家53个中心纳入219例符合改良纽约标准的强直性脊柱炎患者。
- 患者随机接受司库奇尤单抗150 mg、75 mg或安慰剂皮下注射,第16周安慰剂组再随机换用司库奇尤单抗150 mg或75 mg。
- 疗效分析报告初始随机至司库奇尤单抗150 mg组及第16周由安慰剂换用150 mg组,第260周(5年)评估疗效终点。
- 安全性分析纳入所有接受至少一剂司库奇尤单抗的患者。
主要发现
- 219例患者中150例(68%)完成5年治疗,司库奇尤单抗150 mg组106例中82例(77%)完成,75 mg组105例中68例(65%)完成。
- 134例(61%)为anti-TNF初治,85例(39%)为anti-TNF应答不足者。
- 司库奇尤单抗150 mg组5年ASAS20应答为36/54(67%),ASAS40为27/54(50%)。
- 5年时BASDAI50应答为53%(44/83),ASAS 5/6应答为51%(42/83),ASDAS-CRP无活动性疾病为21%(17/81),ASAS部分缓解为25%(21/83)。
临床怎么用
- 司库奇尤单抗150 mg可用于强直性脊柱炎长期治疗,5年维持疗效且安全性可控。
- 治疗中需关注念珠菌感染、炎症性肠病、主要不良心血管事件、葡萄膜炎及肿瘤等不良事件。
局限性
- 疗效数据按观测值报告,未处理缺失数据。
- 5年完成率在150 mg组为77%、75 mg组为65%,存在脱落。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secukinumab, a fully human monoclonal antibody that directly inhibits interleukin 17A, has shown significant and sustained improvement in the signs and symptoms of ankylosing spondylitis over 3 years in the MEASURE 2 study. We report the 5-year (end-of-study) results of subcutaneous secukinumab 150 mg in the MEASURE 2 study. METHODS: MEASURE 2 was a phase 3, double-blind, randomised, placebo-controlled, study done in 13 countries and 53 centres. Patients with ankylosing spondylitis who were 18 years of age or older and fulfilled the modified New York criteria were randomly assigned to receive secukinumab (150 mg or 75 mg) or placebo subcutaneously at baseline and weeks 1, 2, and 3, and then every 4 weeks from week 4. At week 16, patients initially given placebo were randomly assigned again (placebo switchers) to receive secukinumab 150 mg or 75 mg. Efficacy results are reported for patients initially randomised to secukinumab 150 mg and those who switched from placebo to secukinumab 150 mg at week 16. An optional dose escalation from secukinumab 75 mg to 150 mg was initiated beginning week 140. We assessed efficacy endpoints at week 260 (5 years), including Assessment of Spondyloarthritis International Society (ASAS) 20 and ASAS 40, inactive disease according to ankylosing spondylitis disease activity score with C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI50, Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index, Short Form-36 Physical Component Summary, and ASAS partial remission. Analyses were stratified by anti-tumour necrosis factor (TNF) status (anti-TNF-naive and anti-TNF inadequate response). The safety analysis included all patients who received one dose or more of secukinumab. We report data as observed without accounting for missing data. The MEASURE 2 study was registered with ClinicalTrials.gov, NCT01649375. FINDINGS: 219 patients were randomly assigned during the trial and 150 (68%) completed 5 years of treatment, including 82 (77%) of 106 patients in the secukinumab 150 mg group and 68 (65%) of 105 in the secukinumab 75 mg group. Efficacy analysis in the secukinumab 150 mg group included 53 patients who completed the study and one additional patient who was assessed in the treatment period weeks 212-260, but did not complete the study. 134 (61%) of 219 patients were anti-TNF-naive and 85 (39%) were anti-TNF inadequate responders. ASAS responses at 5 years with secukinumab 150 mg were 36 (67%) of 54 patients (ASA20) and 27 (50%) patients (ASAS40). Sustained improvement was observed across other efficacy endpoints with secukinumab 150 mg at 5 years. At 5 years, the proportion of patients achieving efficacy endpoints of BASDAI 50 response was 53% (44/83); ASAS 5/6 response was 51% (42/83); ASDAS-CRP inactive disease was 21% (17/81); and ASAS partial remission was 25% (21/83). Exposure-adjusted incidence rates with any secukinumab dose for selected adverse events were 1·0 per 100 patient-years (95% CI 0·4-1·9) for Candida infections, 0·5 (0·1-1·2) for Crohn's disease, 0·4 (0·1-1·1) for ulcerative colitis, 0·6 (0·2-1·4) for major adverse cardiovascular events, 0·5 (0·1-1·2) for uveitis, and 0·6 (0·2-1·4) for malignant or unspecified tumours. INTERPRETATION: Secukinumab 150 mg provided sustained improvement in the signs, symptoms, and physical function in patients with ankylosing spondylitis after 5 years of treatment. The safety profile of secukinumab remained consistent with previous reports. FUNDING: Novartis Pharma.
引用
- Marzo-Ortega H, Sieper J, Kivitz AJ, et al. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol. 2020. PMID: 38273597. doi:10.1016/S2665-9913(20)30066-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。